3D Systems (NYSE:DDD) Misses Q1 Revenue Estimates, Stock Drops 22.9%
DDD Cover Image
3D Systems (NYSE:DDD) Misses Q1 Revenue Estimates, Stock Drops 22.9%

In This Article:

3D printing company 3D Systems (NYSE:DDD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.1% year on year to $94.54 million. Its non-GAAP loss of $0.21 per share was 44.8% below analysts’ consensus estimates.

Is now the time to buy 3D Systems? Find out in our full research report.

3D Systems (DDD) Q1 CY2025 Highlights:

  • Revenue: $94.54 million vs analyst estimates of $98.31 million (8.1% year-on-year decline, 3.8% miss)

  • Adjusted EPS: -$0.21 vs analyst expectations of -$0.15 (44.8% miss)

  • Adjusted EBITDA: -$23.9 million vs analyst estimates of -$12.36 million (-25.3% margin, 93.3% miss)

  • Operating Margin: -38.9%, in line with the same quarter last year

  • Free Cash Flow was -$36.58 million compared to -$28.74 million in the same quarter last year

  • Market Capitalization: $321.2 million

Dr. Jeffrey Graves, president and CEO of 3D Systems said, “Our first quarter revenues reflect a continuation of challenging top-line pressures as many customers are delaying their capital investments in order to get greater clarity around potential tariff impacts on their manufacturing and distribution strategies. This is in addition to the ongoing geopolitical and broader macroeconomic uncertainty that we have been experiencing for some time. We believe that these factors led to a noticeable dampening of our customers’ near-term capital spending, particularly in consumer-facing and service bureau related end markets. While we were pleased to see this growth in new printer sales for the second straight quarter, the rate was clearly impacted by these capital spending delays. Encouragingly, this growth in printer sales was driven predominantly by our newest hardware systems, as our strengthened technology portfolio delivered strategic wins for all three of our metal printing platforms, and steady growth broadly in Aerospace and Defense markets. These wins bode well for the future, particularly in the high-reliability Healthcare and Industrial markets, which include Aerospace and Defense, and AI infrastructure, areas that have been an increasing focus for us for some time. These trends were true not only in our US markets, but also in Europe, Asia and the Middle East. With regard to materials sales, the decline we experienced was primarily related to short-term inventory management in the dental orthodontics market. More broadly within our Healthcare segment, we delivered impressive results in spite of the broader economy, with 17% growth in our Personalized Healthcare business, and 18% in our manufacturing operations for FDA-approved parts – both crucial elements of our growth strategy moving forward.”